These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 23341160)

  • 41. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
    Deal EN; Micek ST; Reichley RM; Ritchie DJ
    Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
    Prabhu V; Foo J; Ahir H; Sarpong E; Merchant S
    J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
    Cotrina-Luque J; Gil-Navarro MV; Acosta-García H; Alfaro-Lara ER; Luque-Márquez R; Beltrán-García M; Bautista-Paloma FJ
    Int J Clin Pharm; 2016 Feb; 38(1):70-9. PubMed ID: 26474861
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Restriction of third-generation cephalosporin use decreases infection-related mortality.
    Du B; Chen D; Liu D; Long Y; Shi Y; Wang H; Rui X; Cui N
    Crit Care Med; 2003 Apr; 31(4):1088-93. PubMed ID: 12682477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Continuous infusion beta-lactams for intensive care unit pulmonary infections.
    Frei CR; Burgess DS
    Clin Microbiol Infect; 2005 May; 11(5):418-21. PubMed ID: 15819874
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.
    Dulhunty JM; Roberts JA; Davis JS; Webb SA; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Starr T; Paul SK; Lipman J;
    Am J Respir Crit Care Med; 2015 Dec; 192(11):1298-305. PubMed ID: 26200166
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients.
    Shea KM; Cheatham SC; Wack MF; Smith DW; Sowinski KM; Kays MB
    Int J Antimicrob Agents; 2009 Nov; 34(5):429-33. PubMed ID: 19726163
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity.
    Chong Y; Shimoda S; Yakushiji H; Ito Y; Miyamoto T; Kamimura T; Shimono N; Akashi K
    PLoS One; 2013; 8(1):e54190. PubMed ID: 23372683
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia.
    Gruson D; Hilbert G; Vargas F; Valentino R; Bui N; Pereyre S; Bebear C; Bebear CM; Gbikpi-Benissan G
    Crit Care Med; 2003 Jul; 31(7):1908-14. PubMed ID: 12847382
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.
    Bow EJ; Rotstein C; Noskin GA; Laverdiere M; Schwarer AP; Segal BH; Seymour JF; Szer J; Sanche S
    Clin Infect Dis; 2006 Aug; 43(4):447-59. PubMed ID: 16838234
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
    Roy S; Higareda I; Angel-Muller E; Ismail M; Hague C; Adeyi B; Woods GL; Teppler H;
    Infect Dis Obstet Gynecol; 2003; 11(1):27-37. PubMed ID: 12839630
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.
    Georges B; Conil JM; Cougot P; Decun JF; Archambaud M; Seguin T; Chabanon G; Virenque C; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):360-9. PubMed ID: 16119511
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis: A Randomized Controlled Trial.
    Shabaan AE; Nour I; Elsayed Eldegla H; Nasef N; Shouman B; Abdel-Hady H
    Pediatr Infect Dis J; 2017 Apr; 36(4):358-363. PubMed ID: 27918382
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
    Kaye KS; Bhowmick T; Metallidis S; Bleasdale SC; Sagan OS; Stus V; Vazquez J; Zaitsev V; Bidair M; Chorvat E; Dragoescu PO; Fedosiuk E; Horcajada JP; Murta C; Sarychev Y; Stoev V; Morgan E; Fusaro K; Griffith D; Lomovskaya O; Alexander EL; Loutit J; Dudley MN; Giamarellos-Bourboulis EJ
    JAMA; 2018 Feb; 319(8):788-799. PubMed ID: 29486041
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
    Alvarez-Lerma F; Insausti-Ordeñana J; Jordá-Marcos R; Maraví-Poma E; Torres-Martí A; Nava J; Martínez-Pellús A; Palomar M; Barcenilla F;
    Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cefepime use in a pediatric intensive care unit reduces colonization with resistant bacilli.
    Toltzis P; Dul M; O'Riordan MA; Salvator A; Rosolowski B; Toltzis H; Blumer JL
    Pediatr Infect Dis J; 2003 Feb; 22(2):109-14. PubMed ID: 12586972
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prolonged infusion of beta-lactam antibiotics for Gram-negative infections: rationale and evidence base.
    Abdul-Aziz MH; Portunato F; Roberts JA
    Curr Opin Infect Dis; 2020 Dec; 33(6):501-510. PubMed ID: 33009140
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia.
    Fowler RA; Flavin KE; Barr J; Weinacker AB; Parsonnet J; Gould MK
    Chest; 2003 Mar; 123(3):835-44. PubMed ID: 12628886
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC.
    Rhodes NJ; Liu J; McLaughlin MM; Qi C; Scheetz MH
    Diagn Microbiol Infect Dis; 2015 Jun; 82(2):165-71. PubMed ID: 25801780
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.
    Tice AD; Turpin RS; Hoey CT; Lipsky BA; Wu J; Abramson MA
    Am J Health Syst Pharm; 2007 May; 64(10):1080-6. PubMed ID: 17494908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.